Skip to main content

Table 3 Adjusted OR for the CKD according to quartile (Q) classification of TAC by the genotype and dominant model of MnSOD Val16Ala genotype

From: The relationship between MnSOD Val16Ala gene polymorphism and the level of serum total antioxidant capacity with the risk of chronic kidney disease in type 2 diabetic patients: a nested case-control study in the Tehran lipid glucose study

MnSOD Val16Ala (rs4880) OR (95% CI) quartiles P for trend P for interaction
Q1 Q2 Q3 Q4
Genotype
 Val/Val (n = 142) 1 (ref.) 1.79 (0.66–4.83) 2.02 (0.71–5.72) 0.97 (0.36–2.6) 0.055 0.082
 Ala/Val (n = 319) 2.33 (1.18–4.59) 3.48 (1.83–6.63) 6.38 (3.33–13.2) 4.47 (2.64–7.58) 0.063
 Ala/Ala (n = 61) 1.58 (0.33–7.55) 4.75 (0.99–22.67) 4.75 (0.91–24.55) 1.78 (1.06–2.99) 0.133
Dominant Model
 Val/Val (n = 142) 1 (ref.) 1.79 (0.66–4.83) 2.02 (0.71–5.72) 0.97 (0.36–2.6) 0.055 0.254
 Ala/Ala+Ala/Val (n = 380) 1.98 (0.82–4.78) 1.13 (0.48–2.65) 0.66 (0.28–1.59) 0.3 (0.12–0.72) 0.002
  1. ORs (odds ratios and 95% confidence intervals) were calculated using the conditional logistic regression model, adjusted for BMI, energy intake, total Cholesterol, LDL-Cholesterol, triglyceride, Systolic and Diastolic blood pressure, smoking status and medication. The lowest quartile of serum TAC and homozygote genotype with major allele (Val/Val) were used as the reference group